- You can view the full Myriad Genetics Ratings Report.
- Use our diversified services section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Jefferies lowered its price target to $20 on Myriad Genetics (MYGN) stock this morning saying that 'hereditary cancer cracks are emerging.'
Here's a technical look at how to trade some of the most active stocks on the market right now.